Literature DB >> 34152947

Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK.

Gayatri Amirthalingam, Heather Whitaker, Tim Brooks, Kevin Brown, Katja Hoschler, Ezra Linley, Ray Borrow, Colin Brown, Nick Watkins, David J Roberts, Danielle Solomon, Charlotte M Gower, Olivier le Polain de Waroux, Nick J Andrews, Mary E Ramsay.   

Abstract

We describe results of testing blood donors in London, UK, for severe acute respiratory disease coronavirus 2 (SARS-CoV-2) IgG before and after lockdown measures. Anonymized samples from donors 17-69 years of age were tested using 3 assays: Euroimmun IgG, Abbott IgG, and an immunoglobulin receptor-binding domain assay developed by Public Health England. Seroprevalence increased from 3.0% prelockdown (week 13, beginning March 23, 2020) to 10.4% during lockdown (weeks 15-16) and 12.3% postlockdown (week 18) by the Abbott assay. Estimates were 2.9% prelockdown, 9.9% during lockdown, and 13.0% postlockdown by the Euroimmun assay and 3.5% prelockdown, 11.8% during lockdown, and 14.1% postlockdown by the receptor-binding domain assay. By early May 2020, nearly 1 in 7 donors had evidence of past SARS-CoV-2 infection. Combining results from the Abbott and Euroimmun assays increased seroprevalence by 1.6%, 2.3%, and 0.6% at the 3 timepoints compared with Euroimmun alone, demonstrating the value of using multiple assays.

Entities:  

Keywords:  COVID-19; England; SARS-CoV-2; United Kingdom; antibody; coronavirus disease; respiratory infections; serology; seroprevalence; severe acute respiratory syndrome coronavirus 2; surveillance; viruses; zoonoses

Mesh:

Substances:

Year:  2021        PMID: 34152947     DOI: 10.3201/eid2707.203167

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  5 in total

1.  SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).

Authors:  Maria Piron; Mireia Jané; Pilar Ciruela; Luca Basile; Ana Martínez; Lluis Puig; Marta Bes; Silvia Sauleda
Journal:  Blood Transfus       Date:  2022-02-04       Impact factor: 5.752

2.  SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements.

Authors:  Katja Hoschler; Samreen Ijaz; Nick Andrews; Sammy Ho; Steve Dicks; Keerthana Jegatheesan; John Poh; Lenesha Warrener; Thivya Kankeyan; Frances Baawuah; Joanne Beckmann; Ifeanichukwu O Okike; Shazaad Ahmad; Joanna Garstang; Andrew J Brent; Bernadette Brent; Felicity Aiano; Kevin E Brown; Mary E Ramsay; David Brown; John V Parry; Shamez N Ladhani; Maria Zambon
Journal:  Microbiol Spectr       Date:  2022-01-05

3.  Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response.

Authors:  Ashley David Otter; Abbie Bown; Silvia D'Arcangelo; Daniel Bailey; Amanda Semper; Jacqueline Hewson; Matthew Catton; Prem Perumal; Angela Sweed; Deborah Fox McKee; Jessica Jones; Heli Harvala; Abigail Lamikanra; Maria Zambon; Nick Andrews; Heather Whitaker; Ezra Linley; Alexander J Mentzer; Donal Skelly; Julian C Knight; Paul Klenerman; Gayatri Amirthalingam; Stephen Taylor; Cathy Rowe; Richard Vipond; Tim Brooks
Journal:  Microbiol Spectr       Date:  2022-02-23

4.  Transmission of SARS-CoV-2 in the household setting: a prospective cohort study in children and adults in England.

Authors:  Elizabeth Miller; Pauline A Waight; Nick J Andrews; Kelsey McOwat; Kevin E Brown; Höschler Katja; Samreen Ijaz; Mary Sinnathamby; Hannah Cuthbertson; Bassam Hallis; Vaishnavi Parimalanathan; Simon de Lusignan; Jamie Lopez-Bernal
Journal:  J Infect       Date:  2021-08-01       Impact factor: 6.072

5.  Effect of the first year of COVID-19 pandemic on the collection and use of blood components in Colombia monitored through the national haemovigilance system.

Authors:  María-Isabel Bermúdez-Forero; Jonathan-Andrés Soto-Viáfara; Paula-Andrea Gardeazábal-Acuña; Diego-Alexander Anzola-Samudio; Michel-Andrés García-Otálora
Journal:  Transfus Med       Date:  2021-10-24       Impact factor: 2.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.